Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 131 Leukemia 64 Gastrointestinal Stromal Tumors 64 Leukemia, Myeloid, Chronic-Phase 47 Precursor Cell Lymphoblastic Leukemia-Lymphoma 38 Blast Crisis 19 Philadelphia Chromosome 14 Neoplasms 14 Brain Neoplasms 14 Melanoma 12 Neoplasm Metastasis 11 Lung Neoplasms 11 Glioblastoma 11 Leukemia, Myeloid, Acute 10 Leukemia, Myeloid, Accelerated Phase 10 Sarcoma 9 Gliosarcoma 9 Prostatic Neoplasms 8 Leukemia, Myeloid 8 Glioma 8 Central Nervous System Neoplasms 7 Primary Myelofibrosis 6 Oligodendroglioma 6 Dermatofibrosarcoma 6 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 6 Astrocytoma 6 Small Cell Lung Carcinoma 5 Recurrence 5 Ovarian Neoplasms 5

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡